The company is addressing a large unmet medical need: treating acute kidney injury (AKI) and chronic kidney disease (CKD). Thrasos is advancing therapeutic programs, led by THR-184, for renal diseases, including AKI and CDK. Thrasos’ drug candidates have been shown to be orally active and to protect, repair and restore the cell and tissue function in the kidney and other organs.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.